<DOC>
	<DOCNO>NCT00417820</DOCNO>
	<brief_summary>The purpose study assess local tolerability single topical administration BCT194 healthy volunteer , potentially , evaluate safety , tolerability , efficacy multiple topical administration patient psoriasis .</brief_summary>
	<brief_title>Study Safety , Tolerability Efficacy BCT194 Healthy Volunteers Patients With Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>All participant : Healthy male female ( nonchildbearing potential ) subject age 18 45 year age include , good health determine past medical history Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion female subject must surgically sterilize least 6 month prior screen support clinical documentation . Male subject must use doublebarrier local contraception . Body weight must 50 100kg ( inclusive ) participate study Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Psoriasis patient : Diagnosis stable plaque psoriasis without arthritis least 6 month prior screen . Absence clinically relevant abnormality screen laboratory test result hematological ( hemoglobin , white blood cell , neutrophil , platelet ) , renal ( serum creatinine ) hepatic ( aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase , gammaglutamyltransferase , bilirubin ) parameter . Willingness avoid sunbeds unusual sun exposure study period . All participant : Use prescription drug within 4 week prior dose , overthecounter medication ( vitamin , herbal supplement , dietary supplement ) within 2 week prior dose . Paracetamol acceptable , Participation clinical investigation within 4 week prior dose longer required local regulation , limitation participation base local regulation . Donation loss 400 ml blood within 8 week prior first dose , longer required local regulation . Significant illness within two week prior dose . A past personal close family medical history clinically significant cardiac abnormality History : Acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease ) Clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) Known hypersensitivity severe adverse event darifenacin similar drug Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize participation study Immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Drug alcohol abuse within 6 month prior dose . History abnormal skin reactivity UV light . Unusual exposure UV light previous 3 week prior study start , include tanning , sunbeds etc . Psoriasis patient : Currently nonplaque form psoriasis : erythrodermic , guttate , pustular . Currently druginduced psoriasis ( new onset exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) . Used investigational drug within previous 4 week . Recent previous treatment antiTNFÎ± therapy ( biological therapy ) , immunosuppressive agent cyclosporine , mycophenolate , pimecrolimus , tacrolimus . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Safety , tolerability , pharmacodynamics , single administration , BCT194 , healthy volunteer , psoriasis</keyword>
</DOC>